Ignite Creation Date:
2024-05-06 @ 8:24 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06369662
Status:
COMPLETED
Last Update Posted:
2024-04-17
First Post:
2021-07-12
Brief Title:
CD155 Expression in Acute Myeloid Leukemia
Sponsor:
Assiut University
Organization:
Assiut University
Study Overview
Official Title:
Prognostic and Predictive Values of CD155 in Patients With Acute Myeloid Leukemia
Status:
COMPLETED
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Acute myeloid leukemia AML is a heterogeneous hematologic malignancy It is the most common form of acute leukemia among adults In the United States an estimated 19940 people will be diagnosed with AML in 2020
CD155 expression was associated with an unfavorable prognosis in solid tumors such as colon cancer breast cancer lung adenocarcinoma pancreatic cancer melanoma and glioblastoma as it correlated with tumor migration development of metastases tissue and lymph node invasion relapse and poorer survival
CD155 expression was associated with an unfavorable prognosis in solid tumors such as colon cancer breast cancer lung adenocarcinoma pancreatic cancer melanoma and glioblastoma as it correlated with tumor migration development of metastases tissue and lymph node invasion relapse and poorer survival
Detailed Description:
Acute myeloid leukemia AML is a heterogeneous hematologic malignancy It is the most common form of acute leukemia among adults In the United States an estimated 19940 people will be diagnosed with AML in 2020
T-cell exhaustion is a state of decline in T-cell proliferation and function secretion of cytokines and cytotoxicity It is defined by the expression of immune checkpoints including programmed cell death protein-1 PD1 cytotoxic T-lymphocyte-associated protein-4 CTLA4 T-cell immunoglobulin and mucin-domain containing-3 TIM3 lymphocyte-activation gene-3 LAG3 T-cell immunoreceptor with immunoglobulin and ITIM domains TIGIT and CD160 This phenomenon was observed in many cancer cells to escape from antitumor immune responses
The poliovirus receptor PVR also known as CD155 is an immunoglobulin -like adhesion molecule with an important regulatory role in T-cell and natural killer NK cell functions cell migration and proliferation It is a major ligand that is expressed on epithelial and myeloid cells of the tumor PVR is able to bind CD226 DNAX accessory molecule-1 DNAM-1 T-cell-Activated Increased Late Expression Protein TACTILE and TIGIT Binding to DNAM-1 induces the release of pro-inflammatory cytokines and cytotoxicity of T-cells and NK cells T-cell activation while binding to TIGIT induces a rather anti-inflammatory non-proliferative and noncytotoxic profile T-cell exhaustion
CD155 expression was associated with an unfavorable prognosis in solid tumors such as colon cancer breast cancer lung adenocarcinoma pancreatic cancer melanoma and glioblastoma as it correlated with tumor migration development of metastases tissue and lymph node invasion relapse and poorer survival
Stamm et al demonstrated that high CD155 PVR expression correlated with poor outcome in AML Stamm et al also showed that antibody blockade of PVR on AML cell lines or primary AML cells or TIGIT blockade on immune cells increased the anti-leukemic effects mediated by purified CD3 cells in vitro Zhang et al assessed the prognostic significance and immune-associated mechanism of CD155 and identified that CD155 was commonly upregulated in most human cancers including AML and high expression of CD155 was closely correlated with unfavorable clinical outcomes
Our aim is to study the prognostic and predictive values of CD155 expression in AML patients in our locality
T-cell exhaustion is a state of decline in T-cell proliferation and function secretion of cytokines and cytotoxicity It is defined by the expression of immune checkpoints including programmed cell death protein-1 PD1 cytotoxic T-lymphocyte-associated protein-4 CTLA4 T-cell immunoglobulin and mucin-domain containing-3 TIM3 lymphocyte-activation gene-3 LAG3 T-cell immunoreceptor with immunoglobulin and ITIM domains TIGIT and CD160 This phenomenon was observed in many cancer cells to escape from antitumor immune responses
The poliovirus receptor PVR also known as CD155 is an immunoglobulin -like adhesion molecule with an important regulatory role in T-cell and natural killer NK cell functions cell migration and proliferation It is a major ligand that is expressed on epithelial and myeloid cells of the tumor PVR is able to bind CD226 DNAX accessory molecule-1 DNAM-1 T-cell-Activated Increased Late Expression Protein TACTILE and TIGIT Binding to DNAM-1 induces the release of pro-inflammatory cytokines and cytotoxicity of T-cells and NK cells T-cell activation while binding to TIGIT induces a rather anti-inflammatory non-proliferative and noncytotoxic profile T-cell exhaustion
CD155 expression was associated with an unfavorable prognosis in solid tumors such as colon cancer breast cancer lung adenocarcinoma pancreatic cancer melanoma and glioblastoma as it correlated with tumor migration development of metastases tissue and lymph node invasion relapse and poorer survival
Stamm et al demonstrated that high CD155 PVR expression correlated with poor outcome in AML Stamm et al also showed that antibody blockade of PVR on AML cell lines or primary AML cells or TIGIT blockade on immune cells increased the anti-leukemic effects mediated by purified CD3 cells in vitro Zhang et al assessed the prognostic significance and immune-associated mechanism of CD155 and identified that CD155 was commonly upregulated in most human cancers including AML and high expression of CD155 was closely correlated with unfavorable clinical outcomes
Our aim is to study the prognostic and predictive values of CD155 expression in AML patients in our locality
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| SECI-IRB-IORG0006563-545 | OTHER | Scientific Research Unit | None |